INVESTOR ALERT: Pomerantz Investigates BIIB Claims!

Biogen Inc. (NASDAQ: BIIB) is a leading biotechnology company focused on therapies for serious neurological and neurodegenerative diseases, with core franchises in multiple sclerosis (MS) and emerging treatments for Alzheimer’s disease (www.macrotrends.net). The company has recently come under scrutiny after Pomerantz LLP, a shareholder rights law firm, announced an investigation into whether Biogen and its executives engaged in securities fraud or other unlawful practices (www.prnewswire.com). This investor alert was triggered by Biogen’s May 14, 2026 press release of Phase 2 trial results for its Alzheimer’s drug candidate diranersen (BIIB080): Biogen touted the results as “compelling” despite the study missing its primary endpoint (www.prnewswire.com). Biogen’s stock fell over 6% (down $13.16 to $191.37) on the news (www.prnewswire.com), prompting Pomerantz to investigate potential claims on behalf of investors. Below, we review Biogen’s fundamental profile – dividend policy, leverage, valuation – and assess key risks, red flags, and open questions in light of these developments.

Dividend Policy & Shareholder Returns

– No Cash Dividends: Biogen has never paid a cash dividend since its inception and currently has no plans to initiate one (materials.proxyvote.com). Its dividend yield is effectively 0%, underscoring management’s preference to reinvest earnings or return capital through other means. – Share Repurchases: Instead of dividends, Biogen has employed share buybacks as a way to return capital to shareholders. The board authorized a $5 billion repurchase program in 2020, with about $2.1 billion still available as of year-end 2024 (materials.proxyvote.com). Notably, Biogen repurchased no shares in 2023 or 2024, after spending about $750 million on buybacks in 2022 (materials.proxyvote.com). The pause in repurchases coincided with major acquisitions (e.g. Reata and HI-Bio) suggesting cash was prioritized for strategic investments. – Capital Allocation Outlook: Management periodically reviews its capital allocation strategy (including the possibility of dividends, buybacks, or M&A) (materials.proxyvote.com). Given robust cash generation (over $2.87 billion operating cash flow in 2024) (materials.proxyvote.com) and a strengthened cash balance of ~$2.4 billion (materials.proxyvote.com), investors are watching whether Biogen might resume buybacks or consider a dividend in the future. So far, the company appears to favor reinvestment and bolt-on acquisitions over initiating a dividend.

Leverage, Debt Maturities & Coverage

– Debt Profile: Biogen carries a moderate debt load comprised entirely of long-term senior notes totaling ~$6.3 billion as of December 31, 2025 (app.edgar.tools). Recent refinancing has pushed out its maturity schedule: the next major bond maturity is not until 2030 (a $1.5 billion 2.25% note due May 1, 2030) (app.edgar.tools). Subsequent maturities are well staggered (including notes due 2031, 2035, 2045, 2050, 2051, and 2055), giving Biogen a long runway before any large debt repayment comes due. – Refinancing & Liquidity: In 2025, Biogen issued $1.75 billion of new notes to refinance a bond that matured that year (app.edgar.tools) (app.edgar.tools). The company also maintains a $1.5 billion revolving credit facility (due 2029) for liquidity, which had zero drawn as of year-end 2025 (app.edgar.tools). This undrawn revolver and the company’s growing cash reserves provide additional flexibility to weather any short-term funding needs or shocks. – Leverage & Coverage: Biogen’s debt-to-equity ratio stands near 0.5, reflecting a balanced capital structure for a mature biotech. Net debt is lower (~$3.9 billion after cash) and appears manageable relative to earnings – for example, 2024 EBITDA was sufficient to cover annual interest expense many times over (interest costs are only a small fraction of Biogen’s ~$2 billion+ operating income, implying very high interest coverage). Credit agencies have affirmed Biogen’s investment-grade ratings (Moody’s Baa2 and S&P BBB+, both stable outlook) (app.researchpool.com), signaling confidence in the company’s moderate leverage and ability to meet its obligations.

Valuation & Financial Performance

– Revenue & Earnings Trend: Biogen’s revenue in 2024 was $9.68 billion, a slight 1.6% decline from 2023 as growth in new products failed to fully offset declining sales in its legacy MS portfolio (materials.proxyvote.com). Net income improved in 2024, helped by cost cuts – diluted EPS was $11.18, up 40% year-over-year (materials.proxyvote.com) (2023 earnings were depressed by one-time charges related to acquisitions and Aduhelm). For 2025, analysts noted continued headwinds in older drugs but anticipated contributions from newly launched therapies; actual 2025 EPS came in lower (around ~$8.79 TTM by Q4 2025) (www.macrotrends.net) due in part to heavy amortization of acquired intangibles and upfront R&D expenses. – Current Valuation Multiples: At a stock price near $190–$200 in mid-2026, Biogen trades at roughly 20× trailing earnings (www.finanzen.net). This P/E is in line with many pharma/biotech peers – for context, large-cap peer Gilead Sciences trades around 17× earnings (www.macrotrends.net), while Amgen is about 24×. Biogen’s market capitalization is ~$25–30 billion, which is roughly 2.5–3× annual sales. On an enterprise basis (net of cash and debt), the stock is valued at ~12–15× EBITDA – a reasonable multiple reflecting its stable cash flows but tempered growth prospects. – Cash Flow Yield: An important valuation angle for Biogen is its strong cash generation relative to market value. In 2024, operating cash flow was nearly $2.9 billion (materials.proxyvote.com); after capital expenditures, free cash flow yield is on the order of 9–10% – quite robust. This supports the notion that Biogen’s stock might be undervalued on a cash flow basis if its pipeline delivers future growth. However, investors remain cautious given recent execution missteps and pipeline uncertainties (discussed below). – Comparative Factors: Biogen’s valuation also hinges on expectations for its Alzheimer’s franchise. The stock saw high volatility around Alzheimer’s drug news – e.g. it spiked above $250 in 2023 on hopes for Aduhelm/Leqembi, then fell below $150 in 2025 when those hopes dimmed (www.macrotrends.net). Today’s mid-teens earnings multiple suggests the market has adopted a “wait-and-see” stance: pricing Biogen closer to a value stock than a high-growth biotech. If its new therapies (like Leqembi, diranersen, or the acquired Skyclarys for FA) show strong results, there could be upside to earnings and a re-rating; conversely, further disappointments could keep the valuation depressed.

Risks and Red Flags

– Regulatory Investigations: Biogen faces legal and regulatory scrutiny on multiple fronts. In February 2024, the U.S. Department of Justice issued a subpoena seeking information on Biogen’s business operations in certain foreign countries (www.prnewswire.com). While details are not fully disclosed, this raises the possibility of an FCPA (anti-bribery) investigation, a risk many big pharma companies have faced (www.fiercepharma.com). Biogen also disclosed cooperation with the SEC on this matter (www.fiercepharma.com). Ongoing government probes create uncertainty – potential outcomes range from fines or operational changes to reputational damage, depending on what (if anything) is found. – Shareholder Litigation: The Pomerantz investigation itself is a red flag, as it indicates shareholder concern about Biogen’s disclosures. The firm is examining whether Biogen misled investors by portraying the diranersen Phase 2 results too optimistically despite missing the primary endpoint (www.prnewswire.com). If evidence of misleading statements or omitted material facts emerges, Biogen could face a securities class action lawsuit. Separately, Biogen has been involved in suits over its prior Alzheimer’s drug Aduhelm: investors alleged the company wasn’t fully transparent with data during the FDA approval process (www.fiercepharma.com). (An earlier suit over Aduhelm disclosures was largely dismissed, but part of it was revived on appeal (www.fiercepharma.com).) These legal battles pose financial risk (settlements or judgments) and highlight governance concerns about management’s communication practices. – Pipeline and Clinical Trial Risk: Biogen’s future hinges on its R&D pipeline, which comes with high risk. The recent diranersen (BIIB080) trial illustrates this – despite some positive biomarker signs, the missed endpoint casts doubt on the drug’s efficacy (www.prnewswire.com). Biogen is forging ahead to Phase 3 based on subgroup and biomarker data (www.globenewswire.com) (www.globenewswire.com), but there is no guarantee of success. Failure of this program would be a setback in Alzheimer’s, a field where Biogen is trying to establish leadership (alongside partner Eisai’s Leqembi). Beyond Alzheimer’s, Biogen is also developing or launching treatments for ALS (Qalsody), depression (Zurzuvae via Sage), and neuromuscular disorders – each with uncertainty around clinical success, regulatory approval, and market uptake. High R&D spending with uncertain outcomes is an inherent risk for biotech investors. – Competitive & Market Pressures: Biogen’s core products face erosion from competition and generics. Its MS franchise (Tecfidera, Tysabri, Avonex, etc.) has seen sales decline ~7% in 2024 (materials.proxyvote.com) due to newer rivals and patent expirations. Spinraza (spinal muscular atrophy) revenues are also pressured by gene therapies and oral competitors. Even in Alzheimer’s, competition is intensifying: Eli Lilly’s donanemab and others are in late-stage development and could vie with Biogen/Eisai’s Leqembi. Additionally, payer and insurer scrutiny on high-priced drugs (especially Alzheimer’s therapies) poses pricing and reimbursement risk – Medicare has been cautious about covering Aduhelm/Leqembi, and could limit uptake if real-world benefits are unclear. These competitive and market factors could impede Biogen’s revenue growth and margin stability. – Management and Execution: Biogen’s management has had credibility challenges in recent years. The Aduhelm episode – pushing through an FDA approval against advisory panel consensus – drew heavy criticism and damaged the company’s reputation (www.fiercepharma.com) (www.fiercepharma.com). The subsequent commercial flop of Aduhelm (minimal sales due to physicians’ reluctance and lack of insurance coverage) revealed strategic missteps. While a new CEO took the helm in late 2022 aiming to refocus the company, investors remain wary. The handling of the diranersen trial communications (“compelling” vs. actual results) further underscores the need for improved transparency. Any future miscommunication or overly rosy projections could be a red flag, so management’s execution and candor are key watch areas moving forward.

Open Questions for Investors

– Outcomes of Investigations: What will come of the DOJ and SEC investigations into Biogen’s foreign operations? If evidence of wrongdoing (e.g. overseas kickbacks or bribery) is found, could Biogen face significant fines or sanctions, or will the probe close without major findings? Similarly, will the Pomerantz-led inquiry result in a formal class-action lawsuit, or will Biogen demonstrate that its disclosures were in line with legal requirements? These questions hang over the stock, and any resolution (or lack thereof) could move the share price. – Alzheimer’s Franchise Trajectory: How successful will Biogen be in the Alzheimer’s space over the next few years? Leqembi (lecanemab, with partner Eisai) has launched – can it achieve significant adoption and reimbursement to become a multi-billion dollar product, or will safety, cost, and competition limit its potential? And regarding diranersen, will Biogen’s bold decision to advance to Phase 3 pay off with positive results, or is the drug likely to stumble given the Phase 2 miss? The answers will greatly influence Biogen’s growth outlook and investor sentiment, as Alzheimer’s is a key narrative for the company’s future. – Sustainability of Core Business: Can Biogen stabilize or replace the declining revenues from its aging MS and SMA drugs? The company is investing in new areas (psychiatry, immunology, rare diseases – e.g. the Reata acquisition brought Skyclarys for Friedreich’s ataxia, and the Sage collaboration added Zurzuvae for depression) – but will these newer products gain enough traction? Investors are asking if Biogen’s next-generation portfolio can ramp up fast enough to offset losses in its legacy franchises. Progress on product launches and sales in 2026–2027 will be critical to watch. – Capital Allocation & Shareholder Returns: With substantial cash flow and a healthier balance sheet, how will Biogen deploy its capital? Will it resume share buybacks, initiate a dividend, or pursue further M&A to bolster its pipeline? The company’s choices will signal management’s confidence in internal R&D vs. the need to buy growth. Notably, Biogen’s lack of a dividend is unusual among large-cap pharma/biotech peers – if growth remains elusive, pressure could mount to return cash to shareholders. This remains an open question, tied to the strength of Biogen’s pipeline and strategic direction under its current leadership. – Valuation Gap – Value Play or Value Trap?: Lastly, is Biogen’s stock undervalued or appropriately discounted? Bulls might argue the company trades cheaply relative to its cash flows and pipeline optionality (e.g. a successful Alzheimer’s drug could unlock significant upside). Bears focus on the string of setbacks and uncertainties – fearing Biogen could be a “value trap” if pipeline wins don’t materialize. With a P/E around 18–20 and no dividend, Biogen sits in a middle ground – not expensive, but not obviously mispriced given its risk profile. The coming year or two, with Phase 3 trial readouts and legal developments, should provide clarity on which way this valuation gap will close. Investors will be keenly watching those inflection points to judge whether Biogen can turn the corner or if caution is still warranted.

Sources: Biogen Annual Report and SEC filings (materials.proxyvote.com) (materials.proxyvote.com) (materials.proxyvote.com); Pomerantz LLP investor alert press release (www.prnewswire.com); Company press release on Phase 2 trial results (www.globenewswire.com) (www.globenewswire.com); Moody’s and S&P credit ratings updates (app.researchpool.com); FiercePharma and Reuters coverage of DOJ/SEC investigations (www.fiercepharma.com) (www.fiercepharma.com) (www.fiercepharma.com); Macrotrends and financial data for market and valuation metrics (www.macrotrends.net) (www.macrotrends.net).

For informational purposes only; not investment advice.